[Remote] Business Development Manager at Asimov

United Kingdom

Apply Now

Not SpecifiedCompensation

Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Synthetic BiologyIndustries

Requirements

Candidates should possess 4+ years of commercial experience in biotechnology, CDMO/CRO services, or life sciences tools organizations, with a total of 8 years in the biotechnology, bioproduction, or life sciences industries. A proven track record in selling bespoke technical services, navigating complex sales cycles, and a deep understanding of the biotherapeutics manufacturing landscape are essential. Strong networking skills within the biopharma services and tools market, demonstrated expertise in growing long-term client relationships, and technical acumen in cell line development, CMC, process development, and biologics/viral vector manufacturing are required. A scientific or technical background in life sciences is preferred, with advanced degrees being a plus.

Responsibilities

The Business Development Manager will drive revenue growth by developing and executing territory expansion strategies to secure new opportunities and increase market presence within the European biopharma ecosystem. They will build and nurture client relationships, effectively communicate Asimov's platform technologies and their benefits, and own the commercial deal process by shaping partnership strategy and developing deal structures. Additionally, the role involves representing Asimov at industry events to enhance visibility and reputation, and contributing to a collaborative culture by sharing insights and supporting peers.

Skills

Business Development

Sales

Relationship Management

Biopharma

Synthetic Biology

Negotiation

Strategic Planning

Market Awareness

Asimov

Synthetic biology solutions for biopharmaceuticals

About Asimov

Asimov operates in the synthetic biology field, providing a combination of cells, genes, and software to assist in advanced genetic design. Their products include cloud-based software that allows clients in the biopharmaceutical industry to design, simulate, and optimize genetic systems. Additionally, they offer engineered GMP host cells that are used for therapeutic applications. Asimov distinguishes itself from competitors by guaranteeing high titer cell lines for monoclonal antibodies with a promise of '4 g/L or it's free,' which reduces risk for their clients. The company's goal is to enable biopharma companies to produce high-quality protein therapeutics and scalable viral vectors efficiently, supported by their in-house expertise in synthetic biology and process development.

Boston, MassachusettsHeadquarters

2017Year Founded

$199.1MTotal Funding

SERIES_BCompany Stage

AI & Machine Learning, BiotechnologyIndustries

51-200Employees

Risks

Competition from LatchBio's code-free biocomputing infrastructure challenges Asimov's software offerings.

Integration of The Foundry may lead to potential cultural clashes and operational disruptions.

Rapid data generation in synthetic biology may strain Asimov's data processing capabilities.

Differentiation

Asimov offers a '4 g/L or it's free' promise for monoclonal antibodies.

The LV Edge Producer System eliminates GMP plasmid costs and reduces process complexity.

Asimov integrates synthetic biology, computer-aided design, and machine learning for genetic design.

Upsides

Stable cell line development reduces costs and increases scalability in lentiviral production.

Acquisition of The Foundry enhances Asimov's expertise in genetic design and engineering.

Growing biotech investments indicate a robust market for Asimov's engineered cell lines.

Land your dream remote job 3x faster with AI

Try Jobo Free